KRAS and intrahepatic cholangiocarcinoma: The largest of these, reported in abstract form, is a study of 3634 patients with cholangiocarcinomas (number of ICC unspecified), which showed the most common mutations to be TP53 (31%), CDK2NA (29%), KRAS (20%), and ARID1A (17%) [26].